Malignant melanoma is the most aggressive form of skin cancer. The early detection of primary melanoma tumors and metastases using non-invasive PET imaging determines the outcome of this disease. Previous studies have shown that benzamide derivatives (e.g. procainamide) conjugated with PET radionuclides specifically bind to melanin pigment of melanoma tumors.
Introduction
Malignant melanoma is the most aggressive form of skin cancer and it is associated with high mortality [1] . The prognosis of patients with melanoma metastases is very poor. The five-year survival rate is between 5 and 19% when widespread metastatic lesions are present in several organs (e.g.: brain, liver, lung) largely reducing the length of patient survival [2] . Because of its high metastatic potential the early detection of small metastasis using high-resolution imaging techniques (e.g.: Positron Emission Tomography-PET; Magnetic Resonance Imaging-MRI) is critical in patient survival [3, 4] .
In routine clinical use 2-[ 18 F] fluoro-2-deoxy-d-glucose ( 18 FDG) is the most commonly used probe for PET imaging, however, 18 FDG -as a biomarker of glucose metabolism -is not tumor-and hereby, not melanoma-specific [5] . Recently, several radiolabeled carrier molecules, such as melanoma-selective antibodies [6] , ␣-MSH receptor ligands [7] and benzamide derivatives [8, 9] have been tested for melanoma imaging and radiotherapy. As a potential target molecule melanin plays an important role in PET imaging of malignant melanoma. Due to its chemical structure polycyclic aromatic hydrocarbons and organic amines are capable of binding to melanin [10] . It has been shown that benzamide derivatives (e.g.: procainamide) specifically bind to melanin pigment, therefore several radiolabeled benzamide derivatives have been developed for molecular imaging of melanoma such as 68 Ga-SCN-DOTA-PCA, 68 Ga-SCN-NOTA-BZA [8, 9] or [ 18 [11] .
For monitoring malignancies or functional disorders, nuclear medicine applies different radionuclides. The most frequently used radionuclides for PET are cyclotron produced: 11 C (t 1/2 = 20 min), 13 N (t 1/2 = 10 min), 15 O (t 1/2 = 2 min), and 18 F (t 1/2 = 110 min). These non-metallic radioisotopes are dominantly introduced into the biological carriers by means of covalent bonds. The other way for radiolabeling is the use of radiometals, such as 64 Cu, 68 Ga, and 86 Y. Among these radiometals 68 Ga (t 1/2 = 68 min) is an outstanding radioisotope for molecular imaging due to its significant 89% positron yield. Moreover, 68 Ga is easily obtained from 68 Ge/ 68 Ga generator without the establishment of expensive cyclotron and synthesis facility [12] .
The most common way of radiolabeling with radiometals (e.g.: 68 Ga) is the application of bifunctional chelators (BFCs) [13] . BFCs responsible for dual role, they have a reactive functional group to form stable covalent bond with the biological vector and they have a strong metal chelating property also. The first "universal" ligand for imaging applications was the 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and it became one of the most popular macrocyclic chelators for the complexation of radiometals during the last decades [14] . However, in 68 Ga radiolabeling DOTA does not show ideal properties, for the effective complexation elevated temperature is essential. Triazacyclononane derivatives (e.g., 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) and 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA)) provide a smaller coordination pocket and grant higher thermodynamic stability for gallium-complexes [14, 15] and with these structures the labeling at room temperature is also an option [16] .
Furthermore, among the open chain chelators N,N'-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid (HBED-CC) is a highly effective chelator for 68 Ga-labeling, which has an extremely high thermodynamic stability constant [17] . The labeling conditions are mild due to the acyclic structure [18] and the given Ga-complex has high kinetic inertness at physiological pH [19] which is essential for in vivo applications. Nevertheless, recently it has been shown that the chelator-systems can play also the role of the pharmacokinetic modifier, the application of different BFC can affect the accumulation pattern also of the entire molecule [20] . Therefore, the aim of this study is to investigate the effect of HBED-CC-conjugation to a low-molecular weight compound procainamide (PCA) and to compare its radiochemical and biological properties with our existing NODAGA-conjugated analogue.
Materials and methods

Chemicals
For the 68 Ga labeling procedures: ACS grade water for ultratrace analysis -Sigma-Aldrich Kft. (Budapest, Hungary) -Ultrapur HCl and Suprapur NaOH*H 2 O were purchased from Merck Kft. (Budapest, Hungary). HBED-CC-tris(tBu)ester was acquired from ABX GmbH (Germany, Radeberg). All other chemicals were the products of Sigma-Aldrich Kft. (Budapest, Hungary) and they were used without further purification.
Synthesis of HBED-CC-tris(tBu) tetra-fluoro-phenyl ester
70 mg (100 mol) of N,N'-Bis[2-hydroxy-5-(carboxyethyl)-benzyl]ethylenediamine-N,N -diacetic acid, tris tert-butyl ester (HBED-CC-tris(tBu)ester) was dissolved in 1 ml acetonitrile (MeCN) and 20 mg (120 mol) of 2,3,5,6-tetrafluorophenol, 23 mg (120 mol) of N-(3-dimethylaminopropyl)-N -ethylcarbodiimide hydrochloride (EDAC) and 50 l (286 mol) of N,Ndiisopropylethylamine (DIPEA) were added. The mixture was stirred for 2 h and then it was evaporated. The crude product was re-dissolved in 0.75 ml ethyl acetate and it was transferred into a silica chromatographic column (3 g solid phase). The column was rinsed with a mixture of ethyl acetate/methanol (10:1) and the product was recovered with a mixture of ethyl acetate/methanol (4:1). The combined organic phases were evaporated to get 68.3 mg of white solid (yield: 80.4%). The compound was reacted further as we received. M w = 849.42 [M+H] + .
2.3. Conjugation reaction of 4-amino-N-(2-diethylaminoethyl)benzamide hydrochloride with HBED-CC-tris(tBu)ester 13.6 mg (50 mol) of 4-amino-N-(2-diethylaminoethyl)benzamide hydrochloride was dissolved in 1 ml of MeCN/0.1 M sodium carbonate buffer (pH 9.5) 9:1 and 65 mg (75 mol) of tetrafluorophenyl ester of HBED-CC-tris(tBu)ester was added to the solution. The pH of this mixture was adjusted to time to time between 8.5 and 9 by means of 2% NaOH solution during the whole procedure (24 h, room temperature). After the completion of the reaction the solvent was evaporated in vacuum and the mixture was dissolved in 4 ml of 75% MeCN. For the cleavage of the -tBu protecting groups 2 ml of trifluoroacetic acid was added and the solution was stirred for 60 min and evaporated to dryness. The solid material was dissolved in water and was purified on a semi-preparative RP-HPLC. The collected fractions were lyophilized. Finally, a 3 mmol/dm 3 of stock solution was prepared for the radiolabeling reactions. The product was characterized by ESI-MS (Shimadzu LCMS IT-TOF Mass Spectrometer, Shimadzu Corp., Tokyo, Japan) and 1 H NMR (Bruker WP 360 SY).
Preparative and analytical RP-HPLC methods for the precursor
In order to purify the precursor HBED-CC-PCA, a KNAUER HPLC system with semi-preparative Supelco Discovery ® Bio Wide Pore C18 column (150 mm × 10 mm; 10 m diameters), and a flow rate of 4.4 ml/min was applied. The conditions of the separation were identical with the applied ones with NODAGA-PCA [21] . The labeling protocol were published earlier by Kertész et al. [21] . Briefly, the 68 Ga was eluted from the generator by using 0.1 M HCl, and fractional elution procedure was applied. 1 ml from the highest activity aliquot was buffered with sodium-acetate (1 M; 0.15 ml, aq.) and the pH of the mixture was adjusted to ∼4.5 by the addition of sodium-hydroxide (2 %, 0.06 ml, aq.). Subsequently, 5 l of a 3 mM NODAGA-PCA or HBED-CC-PCA stock-solution was introduced to the mixture and the reaction was incubated for 5 min at 95 • C. After a short cooling period, the solution was transferred onto a preactivated Oasis HLB 1 cc cartridge, it was rinsed by 2 ml of water for injection. To eluate the activity from the column it was washed with 0.5 ml of isotonic NaCl solution/EtOH 2:1 mixture, and to decrease the alcohol content below 10% the solution was diluted further with 4 times more saline. Finally the solution was sterile filtered. The specific activities of the productions vary between 13 and 17 GBq/mol. The radiochemical purity (%) of the final product was determined by application of an analytical RP-HPLC.
2.6. Determination of the radiochemical purity of 68 Ga-HBED-CC-PCA by analytical RP-HPLC For the quality control of the 68 Ga-labeled radiopharmaceutical we used the identical system described as analytical HPLC, but equipped with a radiodetector. Signals were parallel detected by radiodetector and UV detector (254 nm).
Determination of partition coefficient of 68 Ga-HBED-CC-PCA
This protocol is based on the procedure described earlier [21] . Briefly, the partition coefficient was determined by mixing approximately 1. MBq of the 68 Ga-HBED-CC-PCA complex (10 l) with a mixture of 500 l of 1-octanol and 500 l of PBS solution (pH 7.4) in a centrifuge tube. The mixture was shaken thoroughly for 20 min and then centrifuged at 20.000 rpm/min for 5 min for complete separation of the layers. Aliquots (100 l) were taken from them and the samples were loaded into test tubes; the radioactivity was determined with a Perkin-Elmer Packard Cobra gamma counter.
Determination of in vitro stability of 68 Ga-HBED-CC-PCA
This protocol is based on the procedure described by Kertész et al. [21] . Shortly, the stability of 68 Ga-HBED-CC-PCA was tested in rat serum at 37 • C. Approximately 8 MBq of 68 Ga-HBED-CC-PCA was introduced into mouse serum and was incubated. aliquot from this mixture at different time points (0, 30, 60, 90 and 120 min) was combined with 50 l cold abs. EtOH. Precipitated fraction was pelleted by centrifugation at 20.000 rpm for 5 min. The supernatant was collected, further diluted with water and the radiochemical purity of 68 Ga-HBED-CC-PCA was assessed by means of the analytical RP-HPLC.
Cell culture
Melanin-producing B16-F10 (mouse) and amelanotic A375 and MELUR (human) melanoma cell lines were purchased from the American Type Culture Collection (ATCC). B16-F10 cells were cultured in Dulbecco's Modified Eagle's medium (DMEM, GIBCO Life Technologies) supplemented with 1% (v/v) MEM Non Essential Amino Acid solution (Sigma-Aldrich), 1% MEM Vitamins solution (Sigma-Aldrich), 10% Fetal Bovine Serum (FBS, GIBCO Life technologies) and 1% Antibiotic and Antimicotic solution (Sigma-Aldrich). A375 and MELUR cells were cultured in Dulbecco's Modified Eagle's medium (DMEM, GIBCO Life Technologies) supplemented with 10% Fetal Bovine Serum (FBS, GIBCO Life technologies) and 1% Antibiotic and Antimicotic solution (SIGMA). All cell lines were cultured at regular conditions (5% CO 2 , 37 • C). For in vitro studies and tumor induction the cells were used at 80% confluence and the viability of the cells was always higher than 90%, as assessed by the trypan blue exclusion test. 
In vitro saturation binding studies
Cellular uptake and efflux studies
Method A: B16-F10, A375 and MELUR cells were grown as monolayer in tissue culture flasks (2 × 10 5 cells per T25 flask) for 24 h. 0.37 MBq of 68 Ga-NODAGA-PCA or 68 Ga-HBED-CC-PCA was then added to each flask and cells were further incubated for 30 and 90 min at 37 • C. After the incubation time cells were washed twice with PBS, trypsinized and the cell number was counted. The radioactivity was measured with gamma-counter (Cobra-II, Canberra Packard, USA) for 1 min within the 68 Ga-sensitive energy window and decay-corrected radiotracer uptake was expressed as counts min −1 (10 6 cells) −1 (cpm). The percent uptake (% uptake) was calculated as the percent of the total added radioactivity found in the pellet. For the determination of 68 Ga-NODAGA-PCA and 68 Ga-HBED-CC-PCA efflux the cells growing in monolayer were first loaded with the radioligands (0.37 MBq at 37 • C for 30 and 90 min) then washed twice with PBS. Afterwards, 5 ml DMEM was added to each culture flask and the adherent cells were further incubated for 10 min at 37 • C without radioligands. After the incubation time cells were washed twice with PBS, trypsinized and the cell number was counted. The radioactivity was measured with gamma-counter.
Method B: B16-F10, A375 and MELUR cells were grown as monolayer for 24 h. Subsequently, cells were trypsinized, centrifuged and resuspended in DMEM and were aliquoted in test tubes at a cell concentration of 1 × 10 6 ml −1 . Each tube was incubated for 30 and 90 min in the presence of 0.37 MBq 68 Ga-NODAGA-PCA or 68 Ga-HBED-CC-PCA at 37 • C. After the incubation time samples were washed 3 times with ice-cold PBS and the radioactivity was measured with gamma counter. For the efflux studies cells were first loaded with radioligands (0.37 MBq at 37 • C for 30 and 90 min). After the incubation time cells were then washed PBS containing 1 mM glucose (gl-PBS) at room temperature. Subsequent centrifugation the supernatant was removed and the cells were resuspended in 2 ml gl-PBS and further incubated for 10 min at 37 • C without radioligands. The efflux was terminated by the addition of ice-cold PBS. The cells were then washed twice with ice cold PBS and the radioactivity was measured using gamma-counter.
2.12.
In vivo tumor models C57BL/6J and CB17 SCID mice were housed under sterile conditions at a temperature of 26 ± 2 • C, with 50 ± 10% humidity and artificial lighting with a circadian cycle of 12 h. Sterile semisynthetic diet (Akronom Ltd., Budapest, Hungary) and sterile drinking water were available ad libitum to all the animals. Laboratory animals were kept and treated in compliance with all applicable sections of the Hungarian Laws and regulations of the European Union. For the induction of in vivo tumor models adult female CB17 SCID (n = 30) and C57BL/6J (n = 20) were used at 10 weeks of age. For the induction of amelanotic tumor models CB17 SCID mice were used; 1 × 10 5 amelanotic Melur or A375 tumor cells in 0.9% NaCl (100 l) were injected into the left shoulder area. To generate melanotic melanoma tumors C57BL/6J mice were subcutaneously injected with B16-F10 tumor cells (1 × 10 5 in 100 l saline) into the left shoulder area. The tumor size was assessed by caliper measurements and was calculated as follows: (largest diameter × smallest diameter 2 )/2. In vivo and ex vivo experiments were carried out 21 ± 2 days after subcutaneous injection of tumor cells at the tumor volume of 110 ± 10 mm 3 .
Animal PET/MRI imaging
Control and tumor-bearing animals were injected with 10.3 ± 0.3 MBq of 68 Ga-NODAGA-PCA or 68 Ga-HBED-CC-PCA via the lateral tail vein. 90 min after radiotracer injection mice were anaesthetized by 3% isoflurane (Forane) with a dedicated small animal anesthesia device and whole body PET scans (20-min static PET scans) were acquired using the preclinical nanoScan PET/MRI system (Mediso Ltd., Hungary). To prevent movement, animals were fixed into a mouse chamber (MultiCell Imaging Chamber, Mediso Ltd., Hungary) and positioned in the center of field of view (FOV). For the determination of the anatomical localization of the organs and tissues, T1-weighted MRI scans were performed (3D GRE EXT multi-FOV; TR/TE 15/2 ms; FOV 40 mm; NEX 2). PET volumes were reconstructed using a three-dimensional Ordered Subsets Expectation Maximization (3D-OSEM) algorithm (Tera-Tomo, Mediso Ltd., Hungary). PET and MRI images were automatically coregistered by the acquisition software (Nucline) of nanoScan PET/MRI instrument. Images were analyzed with the InterView TM FUSION (MedisoLtd., Hungary) dedicated image analysis software. Radiotracer uptake was expressed in terms of standardized uptake values (SUVs). Ellipsoidal 3-dimensional Volumes of Interest (VOI) were manually drawn around the edge of the tissue or organ activity by visual inspection using InterView TM FUSION multi-modal visualization and evaluation software (Mediso Ltd., Hungary). The standardized uptake value (SUV) was calculated as follows: SUV = [VOI activity (Bq/mL)]/[injected activity (Bq)/animal weight (g)], assuming a density of 1 g/mL. Tumor-to-muscle (T/M) ratios were computed as the ratio between the activity in the tumor VOI and in the background (muscle) VOI.
Ex vivo biodistribution studies
One day after in vivo PET/MRI imaging animals were injected intravenously with 10.3 ± 0.3 MBq of 68 Ga-NODAGA-PCA or 68 Ga-HBED-CC-PCA. Mice were euthanized 90 min after the injection of 68 Ga-labeled tracers with 5% isoflurane. Tissue samples were taken from each organ and their weight and radioactivities were measured with gamma counter and DAR (Differential Absorption Ratio) values were calculated ([accumulated radioactivity/g tissue]/[total injected radioactivity/body weight]).
Statistical analysis
Significance was calculated by Mann-Whitney U test and the significance level was set at p ≤ 0.05 unless otherwise indicated. Data are presented as mean ± SD of at least three independent experiments.
Results
Chemical and radiochemical synthesis
HBED-CC-PCA was prepared by a conjugation of 4-amino-N-(2-diethylaminoethyl)benzamide hydrochloride and HBED-CCtris(tBu)-ester (Fig. 1.) and a subsequent protecting group removal. The final product was purified by semi-preparative RP-HPLC. The purity of HBED-CC-PCA was checked by analytical HPLC, and it proved to be better than 98%. The chemical structure of the product was assessed by 1 . We have performed a manual protocol for radiolabeling and the overall reaction time of producing 68 Ga-HBED-CC-PCA was 15 min including the reformulation step also. The decay corrected yield was 65.87 ± 8.25% (n = 7) and the radiochemical purity was at least 98%. The retention factor of the active compound was 9.5 min. The specific activity of the product was 14.81 ± 1.71 GBq/mol. The quality control measurements demonstrated that in the final product all of the isomers exist in different ratios.
Partition coefficient and in vitro stability of 68 Ga-HBED-CC-PCA
The partition coefficient (log P) of 68 Ga-HBED-CC-PCA was determined to be −2.19 ± 0.12. In comparison with the 68 Ga-NODAGA-PCA (−2.79 ± 0.10; [21] ) it means that the new compound has a bit higher lipophilicity, but the compound is still hydrophilic. Furthermore, in order to measure the stability of the newly labeled compound in mouse serum at 37 • C, analytical radio-HPLC was used. After 2 h of incubation in mouse serum, approximately 75% of the original compound was found intact.
In vitro studies
In vitro saturation binding studies showed a positive correlation between the concentration of 68 Ga-NODAGA-PCA and its binding using B16-F10 cells (Fig. 2A) . Similar correlation was found using 68 Ga-HBED-CC conjugated PCA, but significantly lower binding was observed (Fig. 2B) . The melanin specificity of 68 Ga-NODAGA-PCA and 68 Ga-HBED-CC-PCA was investigated using melanotic B16-F10 and amelanotic A375 and Melur cell lines. Cellular uptake and efflux was investigated using melanoma cells in suspension and in monolayer (see Materials and methods: Method A and B in Cellular uptake and efflux studies). In suspension (using Method A) the accumulation of 68 Ga-NODAGA-PCA and 68 Ga-HBED-CC-PCA in B16-F10 cells were significantly higher (p < 0.05 and p < 0.01) than in amelanotic A375 or Melur cells at each time point (Fig. 2C, D) . In experiments where the cellular uptake of the two melanin specific radiotracer was compared, we found that 68 Ga-NODAGA-PCA accumulation in B16-F10 cells was significantly higher (p < 0.001) (1.56 ± 0.39 at 30 min; 2.58 ± 0.69 at 90 min) than the accumulation of 68 Ga-HBED-CC-PCA (0.06 ± 0.017 at 30 min; 0.17 ± 0.03 at 90 min). Similar results were found when plated cells were used (Method B) for the determination of the melanin specificity of the two radiolabeled compounds (Fig. 2E, F) . When melanoma cells in monolayer were used for cellular uptake studies, we found significantly higher (p < 0.01) 68 Ga-NODAGA-PCA accumulation in melanin containing B16-F10 cells (1.97 ± 0.44 at 30 min; 3.61 ± 0.46 at 90 min) than in amelanotic A375 (0.30 ± 0.09 at 30 min; 0.27 ± 0.18 at 90 min) or Melur (0.18 ± 0.07 at 30 min; 0.31 ± 0.24 at 90 min) cells. In melanotic B16-F10 cells the 68 Ga-NODAGA-PCA accumulation was approximately seven-fold higher at each time point than the 68 Ga-HBED-CC-PCA uptake confirming the higher melanin specificity of the NODAGA chelator containing radiotracer. In addition, relatively higher 68 Ga-NODAGA-PCA and 68 Ga-HBED-CC-PCA accumulation was observed using melanoma cells in monolayer than in suspension. In washout (efflux) experiments cells were first loaded with 68 Ga-NODAGA-PCA or 68 Ga-HBED-CC-PCA, and after extensive washing rounds the cells were further incubated for 10 min without radioactivity. Using this method both in suspension and monolayer significant (p ≤ 0.01) differences were found between the 68 Ga-NODAGA-PCA accumulation of melanin positive and negative cell lines (Fig. 2C, E) . Despite the lower uptake of 68 Ga-HBED-CC-PCA in melanoma cells, in efflux studies the melanin-containing B16-F10 cell line showed significantly (p ≤ 0.05) higher 68 Ga-HBED-CC-PCA content at each time point than the melanin negative A375 and Melur cell lines both in suspension (Fig. 2D ) and in monolayer (Fig. 2F) confirming the melanin specificity of 68 Ga-HBED-CC-PCA.
Biodistribution studies in control mice
Whole body PET/MRI imaging and ex vivo organ distribution studies were performed 90 min after intravenous injection of 10.3 ± 0.3 MBq 68 Ga-NODAGA-PCA or 68 Ga-HBED-CC-PCA using healthy C57BL/6 mice. Representative coronal PET/MRI images are shown in Fig. 3 . By the qualitative analysis of PET images the urinary system (kidneys and urine) were clearly visualized. Low radiotracer accumulation was observed in the abdominal and thoracic regions using both radiotracers after 90 min incubation time (Fig. 3) .
In vivo PET/MRI organ distribution results correlated well with the ex vivo data shown in Fig. 3C . For ex vivo distribution studies healthy control animals were sacrificed 90 min after radiotracer injection, and after dissection the accumulated activities of the organs and tissues were assessed by gamma counter. By the quantitative analysis no significant differences were found between the DAR values of organs and tissues when 68 Ga-NODAGA-PCA and 68 Ga-HBED-CC-PCA uptake were compared (Fig. 3C) . Remarkable accumulation was observed in kidneys (approx. DAR: 0.2-0.5) and urine (approx. DAR: 44-55) using both radiotracers. In contrast, slight radiotracer uptake was measured with low DAR values in the brain (0.02 ± 0.01), liver (0.05 ± 0.02), intestines (0.04 ± 0.01), spleen (0.03 ± 0.01), lung (0.02 ± 0.01) and muscle (0.01 ± 0.008) using 68 Ga-NODAGA-PCA. Relatively lower accumulation was found in the brain (0.01 ± 0.007), liver (0.02 ± 0.01), intestines (0.03 ± 0.01), spleen (0.01 ± 0.008), lung (0.01 ± 0.008) and muscle (0.01 ± 0.006) when the distribution of 68 Ga-HBED-CC-PCA was assessed.
PET/MRI imaging and ex vivo biodistribution studies of tumor-bearing mice
For the in vivo assessment of the melanin specificity of the Ga-68 labeled PCA tracers B16-F10, A375 and MELUR tumor-bearing animals were injected intravenously with 10.3 ± 0.3 MBq of 68 Ga-NODAGA-PCA or 68 Ga-HBED-CC-PCA and after 90 min incubation time whole body PET scans were acquired using the preclinical PET/MRI system. Representative whole body coronal and axial PET/MRI image of B16-F10 melanoma tumors are shown in Fig. 4 . By the qualitative analysis of the PET/MRI images the subcutaneously growing B16-F10 tumors were clearly visualized with 68 Ga-NODAGA-PCA 90 min after the tracer injection (Fig. 4A, red arrows) . After the quantitative analysis of PET images significant differences (p ≤ 0.01 level) were found between the 68 Ga-NODAGA-PCA (SUVmean: 0.46 ± 0.05, SUVmax: 1.93 ± 0.25) and 68 Ga-HBED-CC-PCA (SUVmean: 0.13 ± 0.01, SUVmax: 0.56 ± 0.11) accumulation in the melanin positive B16-F10 tumors (Fig. 4C) . In addition, when the 68 Ga-NODAGA-PCA uptake of B16-F10 tumors was compared to the muscle (background) activity, we found that T/M SUVmean and T/M SUVmax were 40.7 ± 4.23 and 23.55 ± 3.45, respectively. These T/M SUV values were approximately four-fold higher than that of the 68 Ga-HBED-CC-PCA uptake ratios, where the T/M SUVmean and T/M SUVmax values were 11.43 ± 1.24 and 6.82 ± 0.96, respectively (Fig. 4D) .
In contrast, very low 68 Ga-NODAGA-PCA and 68 Ga-HBED-CC-PCA uptake was observed when subcutaneous melanin negative tumors (MELUR, A375) were investigated using PET/MRI imaging system (Fig. 5) . By the quantitative analysis of PET images we found that the SUV values (Fig. 5E ) and tumor-to-muscle ratios (Fig. 5F ) of negative tumors were significantly (p ≤ 0.01) lower than of the B16-F10 tumors. Furthermore, no significant differences were found between the accumulation of 68 Ga-NODAGA-PCA and 68 Ga-HBED-CC-PCA radiopharmaceuticals in MELUR and A375 tumors. For the investigation of melanin specificity of 68 Ga-NODAGA-PCA and 68 Ga-HBED-CC-PCA ex vivo biodistribution studies were performed 90 min post injection using subcutaneously growing B16-F10 and amelanotic A375 and Melur tumors. Table 1 demonstrates that the 68 Ga-NODAGA-PCA uptake of B16-F10 tumor was significantly (p ≤ 0.01(**)) higher than that of A375 or Melur tumors, confirming the melanin binding specificity of the 68 Ga-NODAGA-PCA ex vivo. By analyzing the tumor-to-muscle ratios, the difference between the B16-F10 and amelanotic tumors was also significant at p ≤ 0.01. 68 Ga-HBED-CC-PCA showed significantly (p ≤ 0.05 (*)) higher uptake in melanin positive B16-F10 tumors than in amelanotic tumors, however the accumulation of 68 Ga-HBED-CC-PCA in melanoma cell lines was lower when DAR values were compared to DAR values of 68 Ga-NODAGA-PCA.
Discussion
The most aggressive form of skin cancer is malignant melanoma. Considering that this malignancy is associated with high mortality, furthermore the prognosis of patients with metastases is very poor, hence the early detection of small matastatic lesions using high-resolution non-invasive imaging techniques (e.g.: PET) is critical in patient survival [11] . Among radionuclides used in PET, the cyclotron independent radionuclide 68 Ga offers a well-established chemistry for the labeling of small molar-weight biomolecules and peptides [22] [23] [24] . 68 Ga-labeled procainamide shows great potential for diagnosis in a variety of melanomas producing melanin pigment. Here we described the radiosynthesis of the melanin specific 68 Ga-labeled HBED-CC-4-Amino-N-(2-diethylaminoethyl)benzamide ( 68 Ga-HBED-CC-PCA) and compared the preclinical evaluation of this product with our existing NODAGA-conjugated analogue 68 Ga-NODAGA-PCA [21] .
The radiosynthesis of the melanin specific 68 Ga-HBED-CC labeled PCA was very similar to our previously described radiotracer 68 Ga-NODAGA-PCA [21] . The quality control measurements confirm that both of the compounds can be produced in the required radiochemical purity (98%), and due to the similar decay corrected yields (approx. 65-68) between the two melanin specific radiotracer the specific activities are also close together (approx. 13-17 GBq/mol). The overall reaction time of producing 68 Ga-HBED-CC-PCA was also 15 min including the reformulation step. Therefore, this synthesis method enables us to produce the 68 Ga-HBED-CC-PCA for preclinical applications fast and easily with high radiochemical purity and specific activity. Furthermore, after 2 h of incubation in mouse serum, still 75% of the original compound was found intact. Interestingly, this finding does not support the experience of Eder et al. [25] that the application of HBED-CC-vs. NODAGA can increase the metabolic stability of the radiotracer but the current compound is still a highly stable molecule, suitable for biological experiments.
For the investigation of the effect of using different chelators on the melanin specificity of 68 Ga-labeled PCA probes melanin positive B16-F10 and melanin negative melanoma cell lines (MELUR, A375) were used both in monolayer and in suspension (Fig. 2) . Previous studies showed that transport processes (uptake/efflux) are different when cells are used in monolayer or in suspension for in vitro investigations [26, 27] . We also found differences between the uptake of the melanin specific radiotracers when the suspension technique (Fig. 2C, D) was compared to the monolayer technique (Fig. 2E, F) . Relatively higher 68 Ga-NODAGA-PCA and 68 Ga-HBED-CC-PCA accumulation was found at each time point when melanoma cells were used as monolayer. From these in vitro data we concluded that monolayer form is more physiological for the adherent melanoma cells. When the uptake of 68 Ga-HBED-CC-PCA was investigated using both in vitro methods (Fig. 2D, F) , we found significantly (p ≤ 0.05 and p ≤ 0.01) higher accumulation in melanin producing B16-F10 cell than in melanin negative MELUR or A375 cells, furthermore, this accumulation increased with time and remained after 10 min efflux. Despite the low accumulation, these uptake results confirmed the melanin specificity of 68 Ga-HBED-CC-PCA. Previous studies also showed [8, 9] , that 68 Ga-labeled benzamide derivatives ( 68 Ga-SCN-NOTA-BZA and 68 Ga-SCN-DOTA-PCA) specifically bind to melanin in B16-F10 melanoma cells and this accumulation increased in a timedependent manner. As our research group and others reported earlier [9, 21, [28] [29] [30] the uptake of 68 Ga-labeled procainamide is mediated by passive diffusion and the log P value of the labeled compounds plays an important role in this process. The log P of 68 Ga-HBED-CC-PCA was −2.19 ± 0.12. In comparison with the 68 Ga-NODAGA-PCA (log P −2.79 ± 0.10) it means that the new compound has a bit stronger lipophilic character, but it is still highly hydrophilic.
As it was expected from the log P value and from the size of the 68 Ga-HBED-CC-PCA in biodistribution studies using healthy mice we found that 68 Ga-HBED-CC-PCA -similarly to the NODAGA conjugated PCA [21] -mainly excreted from the urinary system and low accumulation was observed in other organs and tissues after 90 min incubation time (Fig. 3) . These in vivo and ex vivo results correlated well with several studies [8, 9, 11, 28, 31] where the biodistribution of other radiolabeled ( 18 F, 68 Ga, 125 I) benzamide derivatives were investigated.
The melanoma specificity of 68 Ga-HBED-CC-PCA was investigated by subcutaneous melanoma tumor-bearing mouse models and its biodistribution was compared with that of 68 Ga-NODAGA-PCA. Melanotic B16-F10 (in C57BL/6 mice) and amelanotic A375, Melur tumors (in SCID mice) were investigated 21 ± 2 days after tumor cell inoculation and 20-min static PET/MRI images were obtained 90 min after the i.v. injection of the radiotracers. The melanin containing B16-F10 tumors were clearly visualized by PET/MRI imaging with low background accumulation using both radiotracers (Fig. 4A, B) . In contrast, when amelanotic MELUR (Fig. 5A, B) and A375 (Fig. 5C, D) tumors were used for PET imaging, very low 68 Ga-HBED-CC-PCA and 68 Ga-NODAGA-PCA accumulation was found confirming the melanin specificity of the radiotracers. After the quantitative SUV analysis of in vivo PET/MRI images and analyzing the ex vivo DAR (Table 1 .) data, we found that 68 Ga-HBED-CC-PCA and 68 Ga-NODAGA-PCA uptake in melanotic B16-F10 tumor (Fig. 4C, D) was significantly (p ≤ 0.01) higher than in amelanotic MELUR or A375 tumors (Fig. 5E, F) . Our in vivo and ex vivo data correlated well with other research papers, where 18 F-and 68 Ga-labeled melanin specific benzamide derivatives were investigated and relatively high accumulation was found in melanin containing B16 tumors with excellent tumor-to-background contrast [8, 9, 11, 28, 31] . Despite the moderate accumulation of 68 Ga-HBED-CC-PCA (SUVmean: 0.13 ± 0.01, SUVmax: 0.56 ± 0.11) and 68 Ga-NODAGA-PCA (SUVmean: 0.46 ± 0.06, SUVmax: 1.93 ± 0.25) in subcutaneously growing B16-F10 tumors, we found that the low activity of other tissues allows of high quality images with high contrast. In addition, our molecules produced higher tumor-to-muscle ratios (T/M SUVmean of 68 Ga-NODAGA-PCA and 68 Ga-HBED-CC-PCA was 40.7 ± 4.23 and 11.43 ± 1.24, respectively) than 68 Ga-SCN-DOTA-PCA (9.47 ± 2.36) with a similar chemical structure what was synthesized by [9] .
In this paper significant differences were found between the in vitro, ex vivo and in vivo accumulation of 68 Ga-NODAGA-PCA and 68 Ga-HBED-CC-PCA molecules. Overall, from our data we concluded that procainamide molecule is highly melanin specific, however, the properties of the used bifunctional chelator (BFC) determines the accumulation of the labeled compound in melanin postive melanoma cells and tumors. From an ideal BFC can expect the following properties: -fast complexation at a very low ionconcentration range, preferably at room temperature, -tolerance of a broad pH range, -and selectivity against the endogenous metal ions (Ca or Zn) or potential impurities originated from the production of the radionuclide (Fe or Al) [13, 32] . The final radiolabeled compound should be resistant of the challenge of different endogenous ligands, such as transferrin or lactoferrin [33] . Therefore, the selection of the appropriate chelator is largely dependent on the applied isotope. A huge number of macrocyclic and open chain BFCs have been developed and tested in regard to satisfy the specific requirements mentioned earlier and several modifications were taken in geometries, donor atoms, pendant arms or coordination numbers [14, 23, 34] . The application of acyclic chelators (e.g. HBED-CC) usually grant fast complexation kinetics, but the kinetically inertness of these complexes usually not so high in comparison with the macrocyclic ones (e.g. NODAGA) [35, 36] . Taking into account that the chelator-systems can play also the role of the pharmacokinetic modifier, the application of different BFC can affect the accumulation pattern also of the entire molecule, as the acyclic complexing agent HBED-CC coupled into a PSMA (prostate-specific membrane antigen) inhibitor, can influence the biological properties of the adduct in a positive way. On the other hand a possible drawback in comparison with other clinically approved chelators (e.g. NODAGA) can be that HBED-CC forms three diastereoisomers during gallium complexation. The ratio of the formed isomers depends on the temperature, the pH and the chelator concentration during the complexation reaction [33] . It was recently reported that during the standard labeling protocol, [ 68 Ga]-PSMA-HBED-CC (pH ∼ 4, temperature 95 • C) mainly the thermodynamically favored diastereoisomer was formed; but measurable amount of the other isomers -due to the problematic separation -can be found in the final formulation prepared for the patient [25] . This feature can be the main limitation factor before the extensive application of HBED-CC in preclinical practice, because it has big importance to determine the exact biological activities of the diastereoisomers [25] . Therefore one can conclude that for biological application the selection of BFC depends on a certain treshold of termodinamical stability and kinetic inertness, but after reaching them the main ephasis shift to the ideal pharmacokinetic properties and the preferably uniform product.
Conclusion
In this present study, we compared the synthesis and biological properties of the melanin specific 68 Ga-PCA molecule conjugated with HBED-CC and NODAGA chelators. It became clear that at this region of log P the hydrophilic-lipophilic balance will not predict correctly the transport of the radioligands across the cell membrane and the ligand-binding capacity of the melanin. Therefore, in the melanin producing experimental B16-F10 melanoma tumors the 68 Ga-labeled-PCA conjugated with NODAGA chelator showed higher binding properties with excellent imaging contrast. In conclusion, the present preclinical data has demonstrated a significant difference in the influence of different chelators for 68 Ga-PCA. This result should be taken into account during the development of 68 Ga-labeled melanoma specific probes for PET imaging.
Conflicts of interest statement
We declare that we have no conflict of interest.
